Frequency of homozygous deletion at p16/CDKN2 in primary human tumours

P. Cairns, T. J. Polascik, Y. Eby, K. Tokino, J. Califano, A. Merlo, L. Mao, J. Herath, Robert Brian Jenkins, W. Westra, J. L. Rutter, A. Buckler, E. Gabrielson, M. Tockman, K. R. Cho, L. Hedrick, G. S. Bova, W. Isaacs, D. Sidransky

Research output: Contribution to journalArticle

642 Citations (Scopus)

Abstract

Many tumour types have been reported to have deletion of 9p21 (refs 1- 6). A candidate target suppressor gene, p16 (p16(INK4)a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.

Original languageEnglish (US)
Pages (from-to)210-212
Number of pages3
JournalNature Genetics
Volume11
Issue number2
StatePublished - 1995

Fingerprint

Neoplasms
Suppressor Genes
Tumor Cell Line
Urinary Bladder Neoplasms
Microsatellite Repeats
Prostatic Neoplasms
Breast Neoplasms

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., ... Sidransky, D. (1995). Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics, 11(2), 210-212.

Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. / Cairns, P.; Polascik, T. J.; Eby, Y.; Tokino, K.; Califano, J.; Merlo, A.; Mao, L.; Herath, J.; Jenkins, Robert Brian; Westra, W.; Rutter, J. L.; Buckler, A.; Gabrielson, E.; Tockman, M.; Cho, K. R.; Hedrick, L.; Bova, G. S.; Isaacs, W.; Sidransky, D.

In: Nature Genetics, Vol. 11, No. 2, 1995, p. 210-212.

Research output: Contribution to journalArticle

Cairns, P, Polascik, TJ, Eby, Y, Tokino, K, Califano, J, Merlo, A, Mao, L, Herath, J, Jenkins, RB, Westra, W, Rutter, JL, Buckler, A, Gabrielson, E, Tockman, M, Cho, KR, Hedrick, L, Bova, GS, Isaacs, W & Sidransky, D 1995, 'Frequency of homozygous deletion at p16/CDKN2 in primary human tumours', Nature Genetics, vol. 11, no. 2, pp. 210-212.
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics. 1995;11(2):210-212.
Cairns, P. ; Polascik, T. J. ; Eby, Y. ; Tokino, K. ; Califano, J. ; Merlo, A. ; Mao, L. ; Herath, J. ; Jenkins, Robert Brian ; Westra, W. ; Rutter, J. L. ; Buckler, A. ; Gabrielson, E. ; Tockman, M. ; Cho, K. R. ; Hedrick, L. ; Bova, G. S. ; Isaacs, W. ; Sidransky, D. / Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. In: Nature Genetics. 1995 ; Vol. 11, No. 2. pp. 210-212.
@article{e02330f438ab40f0aea7c34601698456,
title = "Frequency of homozygous deletion at p16/CDKN2 in primary human tumours",
abstract = "Many tumour types have been reported to have deletion of 9p21 (refs 1- 6). A candidate target suppressor gene, p16 (p16(INK4)a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.",
author = "P. Cairns and Polascik, {T. J.} and Y. Eby and K. Tokino and J. Califano and A. Merlo and L. Mao and J. Herath and Jenkins, {Robert Brian} and W. Westra and Rutter, {J. L.} and A. Buckler and E. Gabrielson and M. Tockman and Cho, {K. R.} and L. Hedrick and Bova, {G. S.} and W. Isaacs and D. Sidransky",
year = "1995",
language = "English (US)",
volume = "11",
pages = "210--212",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Frequency of homozygous deletion at p16/CDKN2 in primary human tumours

AU - Cairns, P.

AU - Polascik, T. J.

AU - Eby, Y.

AU - Tokino, K.

AU - Califano, J.

AU - Merlo, A.

AU - Mao, L.

AU - Herath, J.

AU - Jenkins, Robert Brian

AU - Westra, W.

AU - Rutter, J. L.

AU - Buckler, A.

AU - Gabrielson, E.

AU - Tockman, M.

AU - Cho, K. R.

AU - Hedrick, L.

AU - Bova, G. S.

AU - Isaacs, W.

AU - Sidransky, D.

PY - 1995

Y1 - 1995

N2 - Many tumour types have been reported to have deletion of 9p21 (refs 1- 6). A candidate target suppressor gene, p16 (p16(INK4)a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.

AB - Many tumour types have been reported to have deletion of 9p21 (refs 1- 6). A candidate target suppressor gene, p16 (p16(INK4)a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.

UR - http://www.scopus.com/inward/record.url?scp=0029091503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029091503&partnerID=8YFLogxK

M3 - Article

C2 - 7550353

AN - SCOPUS:0029091503

VL - 11

SP - 210

EP - 212

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 2

ER -